Genetic engineering of IgG-glucuronidase fusion proteins
- 14 October 2009
- journal article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 18 (3) , 205-211
Abstract
β-Glucuronidase (GUSB) is a lysosomal enzyme that could be developed as a brain therapy for Type VII Mucopolysaccharidosis. However, GUSB does not cross the blood–brain barrier (BBB). To enable BBB transport of the enzyme, human GUSB was re-engineered as a fusion protein with the chimeric monoclonal antibody (MAb) to the human insulin receptor (HIR). The HIRMAb crosses the BBB on the endogenous insulin receptor, and acts as a molecular Trojan horse to ferry into brain the GUSB. The 611 amino acid GUSB was fused to either the carboxyl or amino terminus of the heavy chain of the HIRMAb. This study illustrates the differential retention of functionality of IgG-enzyme fusion proteins depending on how the fusion protein is engineered.Keywords
This publication has 13 references indexed in Scilit:
- Re-Engineering Biopharmaceuticals for Delivery to Brain with Molecular Trojan HorsesBioconjugate Chemistry, 2008
- Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrierBiotechnology and Bioengineering, 2007
- Lysosomal Enzyme Replacement of the Brain with Intravenous Non-Viral Gene TransferPharmaceutical Research, 2007
- Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood–brain barrierBiotechnology and Bioengineering, 2007
- Humanization of anti‐human insulin receptor antibody for drug targeting across the human blood–brain barrierBiotechnology and Bioengineering, 2006
- Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII miceProceedings of the National Academy of Sciences, 2004
- A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrugBritish Journal of Cancer, 2002
- Biochemical properties of recombinant human β-glucuronidase synthesized in baby hamster kidney cellsBiochemical Journal, 1994
- Enzyme replacement therapy for murine mucopolysaccharidosis type VII.Journal of Clinical Investigation, 1994
- Human blood-brain barrier insulin-like growth factor receptorMetabolism, 1988